Cargando…
A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma
Pleomorphic xanthoastrocytoma (PXA) is a World Health Organization (WHO) Grade II glioma occurring primarily in children and young adults. Most PXAs harbor the known activating mutation BRAF V600E. We report a case of locally recurrent PXA with anaplastic features in a 10-yr-old female. The PXA was...
Autores principales: | Hsiao, Susan J., Karajannis, Matthias A., Diolaiti, Daniel, Mansukhani, Mahesh M., Bender, Julia Glade, Kung, Andrew L., Garvin, James H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334470/ https://www.ncbi.nlm.nih.gov/pubmed/28299358 http://dx.doi.org/10.1101/mcs.a001396 |
Ejemplares similares
-
Diffuse midline glioma with novel, potentially targetable, FGFR2–VPS35 fusion
por: Zanazzi, George, et al.
Publicado: (2020) -
BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma
por: Migliorini, Denis, et al.
Publicado: (2017) -
Targeting SLMAP-ALK—a novel gene fusion in lung adenocarcinoma
por: Pagan, Carlos, et al.
Publicado: (2019) -
BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications
por: Dias-Santagata, Dora, et al.
Publicado: (2011) -
BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma
por: Lukas, Rimas V, et al.
Publicado: (2018)